Journal
PHARMACOLOGY & THERAPEUTICS
Volume 189, Issue -, Pages 173-183Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2018.04.011
Keywords
N-6-methyladenosine; m(6)A methylation; Epitranscriptomics; Methyltransferase; Demethylase; Cancer
Categories
Ask authors/readers for more resources
N-6-methyladenosine (m(6)A), the most prevalent internal methylation in messenger RNA (mRNA) that is deposited by m(6)A methyltransferases, removed by m(6)A demethylases and recognized by different RNA binding proteins, distinguishes the transcripts through multilayer interactions with mRNA processing, export, degradation and translation machineries. m(6)A plays an important role in regulation of gene expression for fundamental cellular processes and diverse physiological functions. Aberrant m(6)A decorations lead to cancer but also have the potential to yield new therapies. This review outlines the evolution of the m(6)A field, formation of key concepts, important open questions and also discusses the molecular basis of mRNA m(6)A modification and its effect in cancer, highlighting the potential of demethylase as a therapeutic target for cancer treatment. (C) 2018 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available